-
Jun 3, 2024 | 
ipwatchdog.com | Colin Kass
“[R]egulators may not care what the ostensible goal of a conspiracy is if they think it might harm competition. Indeed, the law generally does not recognize health and safety as justifications for anticompetitive conduct.”The Federal Trade Commission (FTC) screwed up. At least that’s how it explains what it calls the “lock[ed] in exploitative business models and monopoly power” of today’s internet giants.
-
May 31, 2024 | 
law360.com | Colin Kass |David Munkittrick
By Colin Kass and David Munkittrick (May 31, 2024, 5:00 PM EDT) -- This article is part of a monthly column that considers the significance of recent FTC antitrust announcements. In this installment, we discuss the agency's added scrutiny on pharmaceutical manufacturers' improper or inaccurate listing of patents in the Orange Book.... Law360 is on it, so you are, too.
-
May 31, 2024 | 
law360.co.uk | Colin Kass |David Munkittrick
ADVERTISEMENT Don't want ads? Subscribe or login now. By Colin Kass and David Munkittrick (May 31, 2024, 5:00 PM EDT) -- This article is part of a monthly column that considers the significance of recent FTC antitrust announcements. In this installment, we discuss the agency's added scrutiny on pharmaceutical manufacturers' improper or inaccurate listing of patents in the Orange Book....
-
Oct 4, 2023 | 
ipwatchdog.com | Colin Kass |Eileen McDermott
“There is no reason for the antitrust laws to protect a less-efficient rival from competition just because it’s new, let alone because it’s ‘unproven.’”Just about everyone bundles. It’s about as American as apple pie: if you buy more, you get a better price. Most of the time, that’s a good thing. Consumers benefit from lower prices. The question is, can bundling violate the antitrust laws? It can.
-
Aug 11, 2023 | 
jdsupra.com | John R Ingrassia |Colin Kass |Ben Orlanski
“Merger review is about to get thornier. While the FTC and DOJ have been tightening the merger review process incrementally over the course of the Biden administration, the newly proposed HSR rule changes represent a wholesale rethinking of how merger transactions are notified and filed.
-
Aug 11, 2023 | 
mondaq.com | John R Ingrassia |Ben Orlanski |Colin Kass |Mary Wilks
"Merger review is about to get thornier. While the FTC and
DOJ have been tightening the merger review process incrementally
over the course of the Biden administration, the newly proposed HSR
rule changes represent a wholesale rethinking of how merger
transactions are notified and filed.
-
Jul 27, 2023 | 
mondaq.com | Colin Kass |John R Ingrassia |Timothy Burroughs
On the heels of the historic proposed changes to the
Hart-Scott-Rodino ("HSR") merger review process, the U.S.
Department of Justice Antitrust Division and the Federal Trade
Commission released the 2023 Draft Merger Guidelines for public
comment. The single set of guidelines will replace the former
horizontal and vertical guidelines, becoming the principal resource
for merger review and challenges.
-
Jul 26, 2023 | 
jdsupra.com | Timothy Burroughs |John R Ingrassia |Colin Kass
July 26, 2023 Timothy Burroughs, John Ingrassia, Colin Kass Proskauer Rose LLP + Follow x Following x Following - Unfollow Contact To embed, copy and paste the code into your website or blog: On the heels of the historic proposed changes to the Hart‑Scott‑Rodino (“HSR”) merger review process, the U.S. Department of Justice Antitrust Division and the Federal Trade Commission released the 2023 Draft Merger Guidelines for public comment. The single set of guidelines will replace the former...
-
Jul 26, 2023 | 
natlawreview.com | Colin Kass
Legal DisclaimerYou are responsible for reading, understanding and agreeing to the National Law Review's (NLR’s) and the National Law Forum LLC's Terms of Use and Privacy Policy before using the National Law Review website. The National Law Review is a free to use, no-log in database of legal and business articles. The content and links on www.NatLawReview.com are intended for general information purposes only.
-
Jul 25, 2023 | 
lexblog.com | John R Ingrassia |Colin Kass |Timothy Burroughs
John is a partner at the Firm, advising on the full range of foreign investment and antitrust matters across industries, including chemicals, pharmaceutical, medical devices, telecommunications, financial services consumer goods and health care. He is the first call clients make in matters relating to competition and antitrust, CFIUS or foreign investment issues.
